Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
Syndax Pharmaceuticals, Inc. reported results from its June 10, 2026 annual stockholder meeting, where all proposals passed. Stockholders approved the 2026 Equity Incentive Plan, which reserves 7,200,000 shares of common stock plus shares that may return from expired or forfeited awards under the prior 2015 plan.
They also approved a new 2026 Employee Stock Purchase Plan to replace the 2015 plan, with U.S. and non-U.S. components, both effective June 10, 2026. Stockholders elected all nominated directors, gave advisory approval to executive compensation, and ratified the company’s independent public accounting firm.
Syndax Pharmaceuticals has entered into privately negotiated subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, with expected net proceeds of about $243 million.
The notes are senior unsecured, pay 2.25% interest semiannually starting December 15, 2026, and mature on June 15, 2031, unless earlier converted, redeemed or repurchased. They are initially convertible at 40.3894 shares of common stock per $1,000 principal (an effective conversion price of about $24.76 per share), representing a roughly 35% premium to the June 3, 2026 share price. Under a higher maximum conversion rate of 54.5256 shares per $1,000, up to 13,631,400 shares may be issued.
Syndax may redeem the notes for cash on or after June 20, 2029 if its stock trades at least 130% of the conversion price for a specified period. Noteholders have conversion and repurchase rights upon certain trading, corporate or “fundamental change” events. The company plans to use proceeds for general corporate purposes, including working capital, research and development, commercialization and business development.
Syndax Pharmaceuticals Inc Chief Financial Officer Keith A. Goldan reported an open-market sale of 1,177 shares of common stock at $18.99 per share. According to the footnote, these shares were required to be sold to cover tax withholding obligations from the vesting of restricted stock units. Following the transaction, he held 139,252 shares directly, indicating this was a small, tax-related adjustment rather than a large discretionary sale.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger sold 6,847 shares of common stock in an open-market transaction. The shares were sold at an average price of $18.99 per share. According to the footnote, this sale was made to cover tax withholding obligations tied to vesting restricted stock units, and he continues to hold 484,843 shares afterward.
Point72 reports shared beneficial ownership of Syndax Pharmaceuticals common stock. As of the close of business on March 31, 2026, Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen are reported to beneficially own 1,985,547 shares, representing 2.3% of the class. The filing states the reported position reflects shared voting and shared dispositive power of 1,985,547 shares and that the reporting persons own no shares directly.
The statement lists the filing entities and their roles: Point72 Asset Management (investment manager), Point72 Capital Advisors Inc. (general partner), and Mr. Cohen (controls both). The address for the reporting persons is provided as 72 Cummings Point Road, Stamford, CT 06902. The filing is an amendment to a Schedule 13G and reflects holdings reported for disclosure purposes.
Syndax Pharmaceuticals is asking stockholders to vote at its 2026 virtual annual meeting on June 10, 2026 at 12:00 p.m. EDT. Holders of 88,595,948 common shares as of April 21, 2026 may participate online via meetnow.global/MUGAWRX.
Stockholders will elect two Class I directors (Pierre Legault and CEO Michael A. Metzger) to terms ending in 2029, cast an advisory say-on-pay vote on named executive officer compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026.
The agenda also includes approval of a new 2026 Equity Incentive Plan covering 7,200,000 shares and a new 2026 Employee Stock Purchase Plan, both intended to support ongoing talent attraction, retention and alignment with long-term stockholder value.
Syndax Pharmaceuticals reported strong Q1 2026 growth but remained unprofitable. Total revenue reached $64.9 million, more than triple the $20.0 million reported a year earlier, driven by new cancer medicines Revuforj and Niktimvo.
Revuforj net product revenue was $48.9 million, up sharply as additional indications and greater physician adoption took hold. Collaboration revenue from Niktimvo contributed $15.9 million as its U.S. launch matured. Operating expenses fell modestly to $99.1 million, reflecting lower launch and milestone costs, while research and development spending remained high to fund multiple late‑stage trials.
Syndax narrowed its net loss to $42.7 million from $84.8 million a year earlier, helped by higher sales but partly offset by $11.8 million of royalty interest expense tied to its Royalty Pharma financing. Cash, cash equivalents and short‑term investments totaled $352.1 million as of March 31, 2026, supporting continued commercialization and development plans.